New drug ABBV-319 takes aim at Hard-to-Treat blood cancers
NCT ID NCT05512390
First seen Jan 07, 2026 · Last updated Jun 22, 2026 · Updated 32 times
Summary
This early-stage trial tests an investigational drug called ABBV-319 in about 154 adults with certain B-cell cancers (diffuse large B-cell lymphoma, follicular lymphoma, or chronic lymphocytic leukemia) that have returned or not responded to standard treatments. The study has two parts: first, finding a safe dose, then checking how well that dose controls the cancer. Participants receive the drug by IV every 21 days and are closely monitored for side effects and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Allina Health System /ID# 251782
RECRUITINGMinneapolis, Minnesota, 55407-1321, United States
-
Asan Medical Center /ID# 263220
RECRUITINGSeoul, Seoul Teugbyeolsi, 05505, South Korea
-
Baylor Sammons Cancer Center /ID# 247715
RECRUITINGDallas, Texas, 75246, United States
-
Concord Repatriation General Hospital /ID# 249240
RECRUITINGConcord, New South Wales, 2139, Australia
-
Cross Cancer Institute /ID# 246717
COMPLETEDEdmonton, Alberta, T6G 1Z2, Canada
-
Hadassah Medical Center-Hebrew University /ID# 254885
RECRUITINGJerusalem, 91120, Israel
-
Hospital Universitario Fundacion Jimenez Diaz /ID# 265198
RECRUITINGMadrid, 28040, Spain
Contact Phone: •••-•••-••••
-
Hospital Universitario Marques de Valdecilla /ID# 262826
RECRUITINGSantander, Cantabria, 39008, Spain
-
Memorial Sloan Kettering Cancer Center-Koch Center /ID# 249246
RECRUITINGNew York, New York, 10065-6007, United States
-
Novant Health Presbyterian Medical Center /ID# 246719
RECRUITINGCharlotte, North Carolina, 28204, United States
-
One Clinical Research Pty Ltd /ID# 248392
RECRUITINGNedlands, Western Australia, 6009, Australia
-
Samsung Medical Center /ID# 263294
RECRUITINGSeoul, Seoul Teugbyeolsi, 06351, South Korea
-
Seoul National University Hospital /ID# 263945
RECRUITINGSeoul, Seoul Teugbyeolsi, 03080, South Korea
-
St Vincent's Hospital Melbourne /ID# 247624
RECRUITINGFitzroy Melbourne, Victoria, 3065, Australia
-
Sylvester Comprehensive Cancer Center - University of Miami /ID# 247232
COMPLETEDMiami, Florida, 33136, United States
-
The Chaim Sheba Medical Center /ID# 254884
COMPLETEDRamat Gan, Tel Aviv, 5265601, Israel
-
University Health Network_Princess Margaret Cancer Centre /ID# 243936
RECRUITINGToronto, Ontario, M5G 2M9, Canada
-
University of Arizona Cancer Center - Tucson /ID# 247752
RECRUITINGTucson, Arizona, 85724, United States
-
University of Nebraska Medical Center /ID# 246715
RECRUITINGOmaha, Nebraska, 68198, United States
-
University of Texas Health San Antonio MD Anderson Cancer Center /ID# 256234
RECRUITINGSan Antonio, Texas, 78229, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ABBV-319 (an investigational drug given by IV infusion)
What this could lead to
If it works, this could point toward a new treatment option for people with certain B-cell cancers that have not responded to other therapies.
What could go wrong
This is a very early Phase 1 trial focused on safety and dosing, not yet on effectiveness. The drug may not shrink tumors or could cause serious side effects. Results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.